Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for Vistagen Therapeutics (VTGN) over the last 6 years, with Q4 2025 value amounting to $2.0 million.

  • Vistagen Therapeutics' Current Deferred Revenue fell 2035.86% to $2.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.0 million, marking a year-over-year decrease of 2035.86%. This contributed to the annual value of $2.6 million for FY2025, which is 22718.08% up from last year.
  • Vistagen Therapeutics' Current Deferred Revenue amounted to $2.0 million in Q4 2025, which was down 2035.86% from $2.1 million recorded in Q3 2025.
  • Vistagen Therapeutics' 5-year Current Deferred Revenue high stood at $3.6 million for Q2 2021, and its period low was $712300.0 during Q3 2022.
  • In the last 5 years, Vistagen Therapeutics' Current Deferred Revenue had a median value of $1.4 million in 2021 and averaged $1.7 million.
  • In the last 5 years, Vistagen Therapeutics' Current Deferred Revenue plummeted by 6956.28% in 2021 and then skyrocketed by 22718.08% in 2025.
  • Over the past 5 years, Vistagen Therapeutics' Current Deferred Revenue (Quarter) stood at $1.4 million in 2021, then tumbled by 49.85% to $712300.0 in 2022, then skyrocketed by 147.48% to $1.8 million in 2023, then soared by 42.39% to $2.5 million in 2024, then decreased by 20.36% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q4 2025, $2.1 million for Q3 2025, and $2.5 million during Q2 2025.